Robin-Tobias Jauss
Staff Scientist
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (5)
Year:
2026
Background: PTEN hamartoma tumor syndrome (PHTS) has evolved into an umbrella term for a range of syndromes, characterized by loss-of-function variants in the phosphatase and tensin homolog (PTEN) tumor suppressor gene on chromosome 10q23.31. This can result in a lifelong tumor predisposition in patients. Often, the syndrome is diagnosed in early childhood because of macrocephaly, dermatological findings, or development delay. Since the correlation between phenotype and genotype is weak, and the penetrance is age-dependent, this poses the question of the appropriate timing of potentially invasive and burdensome examinations for early cancer detection. Case: The present report describes an infant with cleft palate associated with PHTS, a rare occurrence, though the initial report of Cowden syndrome already pointed to oromaxillofacial abnormalities. The recent pediatric literature is reviewed to assess which clinical symptoms should raise suspicion of PHTS and may then lead to early genetic counseling. Conclusion: Since the amount of prospective data remains limited, and the estimation of tumor risk during infancy and adulthood is very difficult, we advocate for early and broad genetic testing in suspected cases, to gain more insights into this rare disease and allow for better counseling for patients and their families.
Year:
2025
GRIN2A has previously been identified as frequently mutated in tumor samples, leading to a hypothesized involvement of GRIN2A in tumorigenesis. Pathogenic GRIN2A germline variants, on the other hand lead, to neurodevelopmental disorders, with no evidence for tumor burden. Thus, we aimed for an independent assessment of somatic and germline variation in GRIN2A, hypothesizing that a distinct distribution of somatic variation indicates a tumorigenic effect. All publicly available GRIN2A variants were obtained from ClinVar, gnomAD and Cosmic to account for germline variation in affected individuals and the general population, as well as somatic variation. Functional consequences, mutational hotspots and gene expression were assessed for each dataset to draw conclusions on the potential pathomechanisms of tumorigenesis. Pathogenic germline variants in GRIN2A expose a clear genotype–phenotype association and are predominantly present in functionally relevant domains, while somatic GRIN2A variants exhibit a uniform distribution and no high abundance in functionally relevant domains. The expression of GRIN2A is lower in tumor samples compared to in non-diseased tissues. Given the non-uniform distribution and domain clustering, our results suggest that specific domains of GRIN2A are highly intolerant towards germline variation, while a lack of somatic mutational clustering and functional relevance refutes the previously hypothesized major role of GRIN2A in tumorigenesis.
Year:
2025
Purpose: With exome sequencing now standard, diagnostic labs are in need of a, in principle, to-the-day-accurate list of genes associated with rare diseases. Manual curation efforts are slow and often disease specific, while efforts relying on single sources are too inaccurate and may result in false-positive or false-negative genes. Methods: We established the MorbidGenes panel based on a list of publicly available databases: OMIM, PanelApp, SysNDD, ClinVar, HGMD and GenCC. A simple logic allows inclusion of genes that are supported by at least one of these sources, providing a list of all genes with diagnostic relevance. Results: The panel is freely available at https://morbidgenes.uni-leipzig.de and currently includes 5037 genes (as of October 2024) with minimally sufficient evidence on disease causality to classify them as diagnostically relevant. Conclusion: The MorbidGenes panel is an open and comprehensive overview of diagnostically relevant rare disease genes based on a diverse set of resources. The panel is updated monthly to keep up with the ever increasing number of rare disease genes.
Year:
2024
Purpose With exome sequencing now standard, diagnostic labs are in need of a, in principle, to-the-day-accurate list of genes associated with rare diseases. Manual curation efforts are slow and often disease specific, while efforts relying on single sources are too inaccurate and may result in false-positive or false-negative genes. Methods We established the MorbidGenes panel based on a list of publicly available databases: OMIM, PanelApp, SysNDD, ClinVar, HGMD and GenCC. A simple logic allows inclusion of genes that are supported by at least one of these sources, providing a list of all genes with diagnostic relevance. Results The panel is freely available at https://morbidgenes.uni-leipzig.de and currently includes 4960 genes (as of March 2024) with minimally sufficient evidence on disease causality to classify them as diagnostically relevant. Conclusion The MorbidGenes panel is an open and comprehensive overview of diagnostically relevant rare disease genes based on a diverse set of resources. The panel is updated monthly to keep up with the ever increasing number of rare disease genes.
Year:
2024
Collaborators (6)
Andreas Merkenschlager
Leipzig University
Rami Abou Jamra
University Hospital Leipzig
Laura Licchetta
University of Bologna
Konrad Platzer
University Hospital Leipzig
Vincent Strehlow
-
Bernt Popp
Berlin Institute of Health at Charité - Universitätsmedizin Berlin
Make your next move.
Prepare your application
Review drafts before you send them.